Committee to Examine Need for Legal Controls on Drug Company Promotions
In a landmark ruling, the Supreme Court instructed the Union to form a dedicated committee to study whether a statutory regime is required to regulate the promotional activities of pharmaceutical manufacturers. The three‑member body will investigate practices such as providing free samples, travel facilities, and hospitality to physicians in exchange for prescribing specific medicines.
Justice Sandeep Mehta, who chaired the bench, emphasized that the current regulatory framework only targets doctors who accept benefits, leaving a gap on the corporate side. The committee’s mandate includes gathering inputs from industry representatives, medical associations and consumer groups, after which it will advise the government on possible legislative measures.
The directive comes as the judiciary continues to scrutinise the pricing structure of medicines, especially the stark contrast between the declared maximum retail price and the actual cost of procurement. The court has warned that such mismatches can erode public trust and may even raise doubts about the authenticity of the drugs supplied at unusually low prices.